Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

NCT05077215 is registered in ClinicalTrials.gov with Evergreen Therapeutics, Inc. as lead sponsor.

NCT NCT05077215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05077215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Lead sponsor
Evergreen Therapeutics, Inc.
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
December 31, 2027
Enrollment
450 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial cancer